Boston-based Bicara Therapeutics, a clinical-stage biopharma developing therapies for patients with solid tumors, this week announced the closing of its initial public offering which raised gross proceeds of approximately $362 million. Bicara’s lead asset, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody […]

Moderna used its annual R&D Day to announce program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline including data readouts in the company’s respiratory vaccine portfolio and a revised financial framework. Over the past three years, Moderna’s robust pipeline has achieved milestones across multiple late-stage clinical trials, and its early-stage portfolio […]

Massachusetts added almost 3,000 net new jobs in the biopharma industry in 2023, accounting for nearly 17% of overall job growth in the state. Meanwhile, the research and development workforce grew by 3.7%, even as the national R&D workforce decreased by 0.5%. This is according to the annual MassBio Industry Snapshot which tracks the state’s life […]

Commenting on Biogen’s second quarter, President and CEO Christopher Viehbacher said: “Biogen delivered strong financial performance…thanks to solid execution against our business strategy, which is aimed at transforming the Company to deliver sustainable growth. We saw continued positive momentum across new product launches and are pleased with the trends we see with key products going […]